Clinical Trials Logo

In-Stent Restenosis clinical trials

View clinical trials related to In-Stent Restenosis.

Filter by:

NCT ID: NCT06148441 Not yet recruiting - In-stent Restenosis Clinical Trials

Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention

Start date: January 1, 2024
Phase:
Study type: Observational

To study the relation between ISR and neutrophil-to-lymphocyte ratio (NLR), novel biomarkers (high-sensitivity CRP (hs-CRP), bone morphogenetic protein-2 (BMP-2) and other risk factors (age, sex, smoking, hypertension, diabetes, obesity, chronic kidney disease (CKD; creatinine clearance).

NCT ID: NCT06117150 Not yet recruiting - In-stent Restenosis Clinical Trials

A Pilot Study of the Drug-eluting Coronary Spur StEnt as a Primary trEatment for In-stent Restenosis of the CORONARY Arteries (DEEPER CORONARY)

Start date: April 2024
Phase: Phase 1
Study type: Interventional

To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.

NCT ID: NCT06104007 Recruiting - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study

SFRGENISTA
Start date: August 17, 2023
Phase:
Study type: Observational

The SFRGENISTA study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with coronary in-stent restenosis (ISR).

NCT ID: NCT06090890 Not yet recruiting - In-stent Restenosis Clinical Trials

Anti-inflammatory Therapy for Recurrent In-stent Restenosis

Start date: October 30, 2023
Phase: Phase 4
Study type: Interventional

This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).

NCT ID: NCT05908331 Recruiting - Clinical trials for Coronary Artery Disease

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

MAGICAL ISR
Start date: April 16, 2024
Phase: N/A
Study type: Interventional

A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouchâ„¢ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouchâ„¢ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a maximum of 50 study sites located in the United States. The goal is to establish the safety and efficacy of the MagicTouchâ„¢ sirolimus- coated balloon in treatment of coronary in-stent restenosis (ISR).

NCT ID: NCT05731700 Active, not recruiting - In-stent Restenosis Clinical Trials

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

NCT ID: NCT05656118 Recruiting - In-stent Restenosis Clinical Trials

Safety and Efficacy of Paclitax Coated Balloon in Patients With Coronary In-stent Restenosis (ISR)

GENISPIRE
Start date: August 31, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational study was to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter in coronary in-stent restenosis (ISR) patients. The primary endpoint was target lesion failure (TLF, a composite of cardiac death, target-vessel MI, or target lesion revascularization) at 12 months.

NCT ID: NCT05623995 Recruiting - In-stent Restenosis Clinical Trials

Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Start date: December 15, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients with chronic total occlusions (CTOs) undergoing successful percutaneous coronary intervention (PCI).

NCT ID: NCT05611190 Not yet recruiting - Clinical trials for Coronary Artery Disease

CT-FFR-guided Strategy for In-stent Restenosis

Start date: December 12, 2022
Phase: N/A
Study type: Interventional

This study will be a prospective, randomized clinical trial to compare standard practice guided by usual care testing to CT-FFR-guided management in patients with in-stent restenosis.

NCT ID: NCT05512832 Completed - In-stent Restenosis Clinical Trials

In-stent Restenosis and Pericoronary Fat Attenuation Index

Start date: January 1, 2020
Phase:
Study type: Observational

This study aims to investigate the predictive value of fat attenuation index (FAI) and related radiomics characteristics of pericoronary fat in patients after percutaneous coronary intervention (PCI) for the occurrence of in-stent restenosis (ISR) during the follow-up period (9 to 24 months). The results of this study are expected to provide an early assessment of the inflammation around the coronary lesion segment in patients after PCI, and provide a basis for early targeted intensive drug therapy in clinical practice.